{"id":84756,"date":"2026-09-14T17:44:00","date_gmt":"2026-09-14T17:44:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=84756"},"modified":"2026-09-14T23:58:49","modified_gmt":"2026-09-14T23:58:49","slug":"lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/","title":{"rendered":"Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026\u20132036), as Innovative Therapies Gain Momentum | DelveInsight"},"content":{"rendered":"<p><em>The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The treatment landscape is evolving beyond conventional broad-spectrum immunosuppressants, with approved therapies such as belimumab, voclosporin, and obinutuzumab expanding treatment options for patients with active disease. At the same time, a robust pipeline of therapies such as Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis\/MorphoSys), Cenerimod (Idorsia Pharmaceuticals\/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), and others is expected to further transform disease management.<\/em><\/p>\n<p align=\"justify\">New York, USA, Sept.  14, 2026  (GLOBE NEWSWIRE) &#8212; <b>Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026\u20132036), as Innovative Therapies Gain Momentum | DelveInsight<\/b><\/p>\n<p align=\"justify\"><b><i>The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The treatment landscape is evolving beyond conventional broad-spectrum immunosuppressants, with approved therapies such as belimumab, voclosporin, and obinutuzumab expanding treatment options for patients with active disease. At the same time, a robust pipeline of therapies such as Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis\/MorphoSys), Cenerimod (Idorsia Pharmaceuticals\/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), and others is expected to further transform disease management.<\/i><\/b><\/p>\n<p align=\"justify\">Recently published Lupus Nephritis Market Insights report includes a comprehensive understanding of current treatment practices, lupus nephritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].<\/p>\n<p align=\"justify\"><b>Lupus Nephritis Market Summary<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">The market size for lupus nephritis was found to be <b>USD 2.1 billion<\/b> in the 7MM in 2025.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The United States accounted for the largest lupus nephritis treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The total diagnosed prevalent cases of lupus nephritis in the 7MM were <b>375,800<\/b> \u00a0 in 2025, and this number is projected to increase by 2036.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Key lupus nephritis companies, including <b>AstraZeneca, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, Autolus, AbelZeta, Cabaletta Bio, Fate Therapeutics, <\/b>and others, are actively working on innovative lupus nephritis drugs.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Some of the key lupus nephritis therapies in clinical trials include <b>Anifrolumab (SAPHNELO), Ianalumab (VAY736), Cenerimod, Rapcabtagene autoleucel (YTB323), Iptacopan (FABHALTA), Obecabtagene autoleucel (obe-cel), C-CAR168, Resecabtagene autoleucel (CABA-201), FT819<\/b>, and others. These novel lupus nephritis therapies are anticipated to enter the lupus nephritis market in the forecast period and are expected to change the market.<\/li>\n<\/ul>\n<p align=\"justify\">Discover more about lupus nephritis prevalence statistics @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B2L6AdhDshdJ5shOnlk4h0504iStrtrSbR7tzJYUTkqHu4rU4YqQQ4WQCs8L4sJ84czn1jSNzweQmNcVeKS_UOkgJYhIlnpzQNxwzvK238yZ843z5WgUyPvB5eH6-yzHU_rrngo8YK2fF98AaNY2DmmQ6-4fUN6ZWG-m3SzHGe0x3vdyfvv7hUN-RyTyqBYAg3USOdTgmHkTqgF1m1hEmTs-ac1btvSinmVoooDEkbLliMeBrjMd73vaNu0m5qEfw3-gzA3s4mI-8nliZbbhEtwPTgGPSrYhiHpA2Yx5Br4=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>https:\/\/www.delveinsight.com\/report-store\/lupus-nephritis-market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Key Factors Driving the Growth of the Lupus Nephritis Market\u00a0<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\"><b>Increasing Prevalence of Systemic Lupus Erythematosus: <\/b>The growing prevalence of systemic lupus erythematosus (SLE), a significant proportion of whom develop lupus nephritis, is expanding the patient population requiring treatment. Improved disease recognition and diagnosis are also contributing to greater identification of eligible patients.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Growing Demand for Targeted and Effective Therapies:<\/b> The limitations and safety concerns associated with conventional immunosuppressive treatments have created a need for more targeted therapies. Novel biologics and other advanced treatment approaches are helping address unmet needs in patients with active or difficult-to-manage disease.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Advancements in the Clinical Pipeline: <\/b>A robust pipeline of investigational therapies, including <b>Anifrolumab <\/b>(SAPHNELO; AstraZeneca), <b>Ianalumab <\/b>(VAY736; Novartis\/MorphoSys), <b>Cenerimod <\/b>(Idorsia Pharmaceuticals\/Viatris), <b>Rapcabtagene autoleucel<\/b> (YTB323; Novartis), <b>Iptacopan <\/b>(FABHALTA; Novartis), and others with diverse mechanisms of action, is expected to reshape the lupus nephritis treatment landscape. Ongoing clinical trials and positive study outcomes could introduce new treatment options and intensify market competition.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Growing Interest in CAR-T Therapy for Lupus Nephritis:<\/b> The success of CAR-T therapies in oncology has accelerated interest in their application to autoimmune diseases, including lupus nephritis. Early clinical evidence demonstrating deep B-cell depletion and potential long-term disease control has attracted substantial investment, positioning CAR-T therapy as a promising future disease-modifying approach.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Rising Focus on Personalized Treatment Approaches: <\/b>The heterogeneity of lupus nephritis is driving interest in personalized and targeted treatment strategies. Advances in biomarkers and disease monitoring may help optimize therapy selection and improve long-term patient outcomes.<\/li>\n<\/ul>\n<p><img decoding=\"async\" alt=\"\" data-mce-style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/c35250c0-9d68-4acb-a3ec-acd259f3e475\/lupus-nephritis-market.jpg\" style=\"display:block; margin-left:auto; margin-right:auto;\" data-dpi=\"96\" data-filename=\"Lupus-Nephritis-Market.jpg\" \/><\/p>\n<p align=\"justify\"><i>Aparna Thakur, project manager of forecasting at DelveInsight, said that all CAR-T therapies, C-CAR168, resecabtagene autoleucel, and rapcabtagene autoleucel, obecabtagene autoleucel show promise for treating lupus nephritis, but it is too early to definitively say which is better.\u00a0<\/i><\/p>\n<p align=\"justify\"><b>Lupus Nephritis Market Analysis<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">At present, three therapies have received FDA approval for the treatment of lupus nephritis: <b>belimumab (BENLYSTA)<\/b>, approved in 2020 and subsequently extended to pediatric patients in 2022; <b>voclosporin (LUPKYNIS)<\/b>, approved in 2021 as the first oral therapy specifically indicated for lupus nephritis; and <b>obinutuzumab (GAZYVA\/GAZYVARO)<\/b>, approved in 2025, broadening the range of biologic treatment options available for patients with active disease.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Despite these advances, the existing standard of care for lupus nephritis continues to rely largely on broad-spectrum immunosuppressive agents, which are associated with considerable short- and long-term toxicity.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Growing research efforts have focused on developing targeted therapies designed to modulate specific inflammatory and immune pathways implicated in disease progression.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The lupus nephritis market has also attracted increasing interest from major pharmaceutical companies.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The evolving drug pipeline includes several innovative therapeutic approaches, such as <b>complement inhibitors<\/b> like iptacopan, <b>BAFF-R antagonists<\/b> such as ianalumab, <b>monoclonal antibodies<\/b> including anifrolumab, <b>sphingosine-1-phosphate 1 receptor modulators<\/b> such as cenerimod, and <b>CAR-T therapies<\/b> including resecabtagene autoleucel, rapcabtagene autoleucel, obecabtagene autoleucel, C-CAR168, and mivocabtagene autoleucel.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">These emerging therapies are anticipated to contribute to significant changes in the lupus nephritis treatment landscape through 2036, potentially enabling more targeted, personalized, and effective disease management.<\/li>\n<\/ul>\n<p align=\"justify\">Learn more about lupus and lupus nephritis clinical trials disease mechanism alignment @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YT9go2eRQq829j9D-VfDaiE-f7JDYvURq6mq-twWYVav1pC1VMXLRdZX_q6c8SMRPwIkdHN1VHoDgzju8zMO0iXA1ZEb6Pbs38IuNiQpO2E5Fkj5zv3JEcHNCAgpXyfQSOl7z8AxZ27glfS8Wxwn3l5-AYqJSGiK1BJtUvUEEb_osoLlmLo8k1wdQIEpeP5AA9jpAG2wrrQkKshf4YBw6lFHr6x6eoXwCx_C-8m0SOEAzPeWsAqFhcwN8fWAWejQ\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Lupus<\/b><b> Nephritis Treatment Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Lupus Nephritis Competitive Landscape<\/b><\/p>\n<p align=\"justify\">Some of the lupus nephritis drugs under development include <b>Anifrolumab <\/b>(SAPHNELO; AstraZeneca), <b>Ianalumab <\/b>(VAY736; Novartis\/MorphoSys), <b>Cenerimod <\/b>(Idorsia Pharmaceuticals\/Viatris), <b>Rapcabtagene autoleucel<\/b> (YTB323; Novartis), <b>Iptacopan <\/b>(FABHALTA; Novartis), <b>Obecabtagene autoleucel<\/b> (obe-cel; Autolus), <b>C-CAR168<\/b> (AbelZeta), <b>Resecabtagene autoleucel<\/b> (CABA-201; Cabaletta Bio), <b>FT819 <\/b>(Fate Therapeutics), and others.<\/p>\n<p align=\"justify\"><b>AstraZeneca\u2019s SAPHNELO (anifrolumab)<\/b> is an intravenous, fully human monoclonal antibody that targets Subunit 1 of the Type I interferon (IFN) receptor. By binding to this receptor, the therapy inhibits Type I IFN signaling. Type I IFNs, including IFN-alpha, IFN-beta, and IFN-kappa, are cytokines that play an important role in the regulation of inflammatory responses.<\/p>\n<p align=\"justify\">AstraZeneca is currently assessing SAPHNELO in the Phase III IRIS trial (NCT05138133) for adults with active proliferative lupus nephritis. According to the company\u2019s 2024 full-year results update, topline results from the Phase III IRIS study are expected in 2026.<\/p>\n<p align=\"justify\"><b>Fate Therapeutics\u2019 FT819<\/b> is an allogeneic, off-the-shelf CD19-directed CAR T-cell therapy candidate designed to enhance both safety and therapeutic efficacy. Fate Therapeutics has initiated the Phase II RECLAIM-LN study and treated its first patient to evaluate FT819 in individuals with moderate-to-severe systemic lupus erythematosus (SLE) accompanied by Class III or IV lupus nephritis.<\/p>\n<p align=\"justify\">The open-label trial is expected to enroll approximately 53 patients and will evaluate the safety and efficacy of a single 900-million-cell dose of FT819. The primary endpoint is the percentage of patients achieving a complete renal response at Week 26. The study incorporates recommendations provided by the US FDA as part of FT819\u2019s Regenerative Medicine Advanced Therapy (RMAT) designation.<\/p>\n<p align=\"justify\"><b>Novartis\u2019 Rapcabtagene autoleucel<\/b> is an investigational autologous CD19-directed CAR T-cell therapy developed on Novartis\u2019s T-Charge platform. The treatment uses a patient\u2019s own T cells, which are genetically modified to express a CD19-specific chimeric antigen receptor (CAR), allowing selective targeting and depletion of B cells involved in autoimmune disease. Delivered as a single intravenous infusion, rapcabtagene autoleucel is intended to achieve profound and durable B-cell depletion.<\/p>\n<p align=\"justify\">Novartis is currently investigating rapcabtagene autoleucel in a Phase II clinical study for SLE and lupus nephritis. Based on Novartis\u2019s 2026 interim financial report, the company expects to submit regulatory applications for rapcabtagene autoleucel in lupus nephritis\/SLE in 2028.<\/p>\n<p align=\"justify\">The anticipated launch of these emerging lupus nephritis therapies are poised to transform the lupus nephritis market landscape in the coming years. As these cutting-edge lupus nephritis therapies continue to mature and gain regulatory approval, they are expected to reshape the lupus nephritis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n<p align=\"justify\">To know more about lupus nephritis treatment options, visit @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YT9go2eRQq829j9D-VfDamiP8FrN0p5roGX16T-eOn9rDwywoJu-tobohXL8bxqelJ-4ml3KIyctApzb-OsDHjiOAxVZVudlYUqMSK2QNvneMixaSE4qJr7wTK3pRRGihrlZrgyrASMRZbFqCFap89drQpmahLQRSbX1EqYQCqhC6aX7uoWAodrYNifn-XPemqES0nq_5rpkWQZ_6HFRHuhaC4yXVFIBL5e-KPW4uOOel9__8ZhBIrVxaNqHXTuA\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Lupus Nephritis Drugs<\/b><\/a><\/p>\n<p align=\"justify\"><b>Recent Developments in the Lupus Nephritis Market<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">In <b>August 2026, Fate Therapeutics<\/b> initiated a potentially registrational RECLAIM-LN clinical trial for the treatment of lupus nephritis<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>July 2026, AbelZeta Pharma<\/b> announced that the U.S. FDA has granted clearance under its Regenerative Medicine Advanced Therapy (RMAT) designation for a multicenter, registrational Phase II clinical trial of C-CAR168, an anti-CD20\/BCMA bispecific CAR-T therapy, in patients with lupus nephritis who are refractory to standard treatment.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>July 2026, AbelZeta Pharma<\/b> announced that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted PRIority MEdicines (PRIME) designation to C-CAR168, the company\u2019s novel autologous anti-CD20\/BCMA CAR-T cell therapy, for the treatment of refractory systemic lupus erythematosus (SLE), including patients with or without lupus nephritis (LN).<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>July 2026, Aurinia Pharmaceuticals Inc.<\/b> announced the launch of PRESERVE, a Phase IV, multicenter study evaluating LUPKYNIS\u00ae in combination with belimumab, obinutuzumab, or anifrolumab in patients with lupus nephritis. The study is expected to enroll approximately 150 patients across around 50 sites in the United States, with the primary endpoint assessing the proportion of patients who achieve complete renal response (CRR) at 6 months.<\/li>\n<\/ul>\n<p align=\"justify\"><b>Lupus Nephritis Epidemiology Segmentation<\/b><\/p>\n<p align=\"justify\">The lupus nephritis epidemiology section provides insights into the historical and current Lupus Nephritis patient pool and forecasted trends for the leading markets. US contributed the largest prevalent population of Lupus nephritis, accounting for <b>~57%<\/b> of the 7MM in 2025. These cases are anticipated to increase in the upcoming years.<\/p>\n<p align=\"justify\">The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l7BvIc-79KNerRiIpwqyNO5Vw7tsVRyPEsal5xnIJ3cqaxNjph3ZFrOSRFOOg6u8SvY86kC6wIAKQn4cAfStMC4g2Nmfl5qlmIIrbMLrZpNsKZhpX_3o_Vk7Wfq_N1s-VCJDT7A7xZR9wsi79yyxa9yjmAH2_fro26-Wy7pHWlPlmaOpvGkvFtoSRcz_RTS0zUV-oHiSHJJyaFZoB82zWkFAvu6nKLpGHzzG0yCBiefrCU_Ztujw8ZoNjGDfOnyA\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>lupus nephritis market report<\/b><\/a> proffers epidemiological analysis for the study period 2022\u20132036 in the leading markets segmented into:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">Total Diagnosed Prevalent Cases of Lupus Nephritis<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Age-specific Diagnosed Prevalent Cases of Lupus Nephritis<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Diagnosed Prevalent Cases of Lupus Nephritis by Class<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Total Treated Cases of Lupus Nephritis<\/li>\n<\/ul>\n<p align=\"justify\">Download the report to understand the future of lupus nephritis treatment @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5fN50IwXmY66TbHY0ky1oSUwQZh79RGzUq9yV0mKad9Koshb6BwMvsYMvnC1kPmPWswOjlHOfO6IhjHvHmXFoO60onmX3TtEhyg_3AV13SLwpqnMn5KEj_fCok4u7UqyHlntYEMRsODQfhC7QmIQtFVCsUhuRpuh04RKGmQgNBwji8sSPyrSYZvHxefPrqGCph4wk6qQLvINYXQ5gXs2ECWcjFmiSiY3NwepmJ09Am30Se4Zh2hoXLcFD_2lNERZ\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Treatment for<\/b> <b>Lupus Nephritis\u00a0<\/b><\/a><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Lupus Nephritis Market Report Metrics<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Details<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Study Period<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2022\u20132036<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Lupus Nephritis Market Report Coverage<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Lupus Nephritis Market CAGR (2022\u20132036)<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Lupus Nephritis Market Size in 2025<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">USD 2.1 Billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Lupus Nephritis Companies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">AstraZeneca, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, Autolus, AbelZeta, Cabaletta Bio, Fate Therapeutics, GlaxoSmithKline, Aurinia Pharmaceuticals, Otsuka Pharmaceuticals, Roche, and others<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Lupus Nephritis Therapies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Anifrolumab (SAPHNELO), Ianalumab (VAY736), Cenerimod, Rapcabtagene autoleucel (YTB323), Iptacopan (FABHALTA), Obecabtagene autoleucel (obe-cel), C-CAR168, Resecabtagene autoleucel (CABA-201), FT819, BENLYSTA, LUPKYNIS, GAZYVA\/GAZYVARO, and others<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><b>Scope of the <\/b><b>Lupus Nephritis<\/b><b> Market Report<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">Lupus Nephritis Patient Population Forecast<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Lupus Nephritis Therapeutics Market Size<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Lupus Nephritis Pipeline Analysis<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Lupus Nephritis Market Size and Trends<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Lupus Nephritis Market Opportunity<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Lupus Nephritis Market Unmet Needs<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">KOL\u2019s Views on Lupus Nephritis<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Lupus Nephritis Market Access and Reimbursement<\/li>\n<\/ul>\n<p align=\"justify\">Discover more about next-generation lupus nephritis drugs @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YT9go2eRQq829j9D-VfDau3cpv-NKqcX86uJwz3b4IHWmlqL9RXfdGij1ZLBQdpBrgDvgOQA0D0swOvGZGkOAd5Hh6aGqJUZ5asmHiOLLPg81wAG_fbHR97Cry4sao03a9ujt7gajMSBv5Xgy8C70edHlxoQC16lzOAPPGrhMftteGfwROShNX8b0tnjUiA-syoUwQE9sGyBYVZAVXIp04qdZuv6F5S9EoGPvFD8s2wFcoCWaXbKc_zVOfgM7GSL\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Lupus Nephritis Clinical Trials<\/b><\/a><\/p>\n<p align=\"justify\"><b>Table of Contents<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">1<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Lupus Nephritis Market Key Insights<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Lupus Nephritis Market Report Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Executive Summary of Lupus Nephritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Events<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Epidemiology and Market Forecast Methodology<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Lupus Nephritis Market Overview at a Glance<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Landscape Analysis (By Phase, RoA, and Molecule Type)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Share (%) Distribution of Lupus Nephritis by Therapy in 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Share (%) Distribution of Lupus Nephritis by Therapy in 2036<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Disease Background and Overview of Lupus Nephritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Types of Lupus<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Causes and Risk Factors<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Signs and Symptoms of Lupus Nephritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Classification of Lupus Nephritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Pathophysiology of Lupus Nephritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Biomarkers of Lupus Nephritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Complications of Lupus Nephritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.9<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Diagnosis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.10<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Diagnosis Algorithm<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.11<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Differential Diagnosis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Treatment of Lupus Nephritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Classes III and IV Induction Therapy<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Class V Induction Therapy<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Treatment Options for Kidney Failure<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Treatment Algorithm<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Guidelines of Lupus Nephritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Epidemiology and Patient Population of Lupus Nephritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Findings<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Assumptions and Rationale<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Diagnosed Prevalent Cases of SLE in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Diagnosed Prevalent Cases of Lupus Nephritis in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Treated Cases of Lupus Nephritis in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">The United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.6.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Diagnosed Prevalent Cases of Lupus Nephritis in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.6.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Age-specific Diagnosed Prevalent Cases of Lupus Nephritis in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.6.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Diagnosed Prevalent Cases of Lupus Nephritis by Class in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.6.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Treated Cases of Lupus Nephritis in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">EU4 and the UK<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Japan<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">10<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Patient Journey of Lupus Nephritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Marketed Therapies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Marketed Competitive Landscape<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Voclosporin (LUPKYNIS): Aurinia Pharmaceuticals\/Otsuka Pharmaceuticals<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Drug Description<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Regulatory Milestones<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Other Developmental Activities<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Summary of Pivotal Trials<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Development<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.5.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Trial Information<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Safety and Efficacy<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Analyst Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Belimumab (BENLYSTA): GlaxoSmithKline<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Emerging Lupus Nephritis Drugs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Emerging Competitive Landscape<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Anifrolumab (SAPHNELO): AstraZeneca<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Product Description<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Other Development Activities<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Development<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.3.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Trial Information<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Safety and Efficacy<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Analyst Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Ianalumab (VAY736): Novartis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Iptacopan (FABHALTA): Novartis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Rapcabtagene autoleucel (YTB323): Novartis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Resecabtagene autoleucel (CABA-201): Cabaletta Bio<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">C-CAR168: AbelZeta<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \"><i>List to be continued in the final report<\/i><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Lupus Nephritis Market: 7MM Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Findings<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Lupus Nephritis Market Outlook<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Conjoint Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Lupus Nephritis Market Forecast Assumptions<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.4.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Launch Year and Therapy Uptakes<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of Lupus Nephritis in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Size of Lupus Nephritis by Therapies in 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">United States Lupus Nephritis Market Size<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.7.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of Lupus Nephritis in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.7.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Size of Lupus Nephritis by Therapies in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">EU4 and UK Lupus Nephritis Market Size<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.9<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Japan Lupus Nephritis Market Size<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">14<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Unmet Needs of Lupus Nephritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">15<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">SWOT Analysis of Lupus Nephritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">16<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">KOL Views of Lupus Nephritis\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Access and Reimbursement of Lupus Nephritis Therapies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">The US<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">In EU4 and the UK<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Japan<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Summary and Comparison of Market Access and Pricing Policy Developments in 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Access and Reimbursement of Alport syndrome Therapies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">18<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Bibliography<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">19<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Lupus Nephritis Market Report Methodology<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><b>Related Reports<\/b><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YT9go2eRQq829j9D-VfDau3cpv-NKqcX86uJwz3b4IFoVcyCicXfGzPtqxFL-LXJ4xLUm1ylsoH0CipIl9917o8OZeNlHATemitK9Cwr7xIJEkDpdYw8c7x933W1gtLRHhj8p07e2Zyftw8gSO5-xkJQpQtxQciwoYHEKIwFzaZYsw-fd3nykoFZKqIkdp3ou0WosCDL8wLWZvUy68bz_OuP_sgehQGXUj-H2uTbfIcDU4LbdhxNSsEhcP8R8TmseUoSp_GniSBwT5dd-D1ncrJnk3caxrD6NcweUY9ptcc=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Lupus Nephritis Clinical Trial Analysis\u00a0<\/b><\/a><\/p>\n<p align=\"justify\"><b>Lupus Nephritis Pipeline Insight \u2013 2026<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key lupus nephritis companies, including <b>Novartis, Simcere Pharmaceutical Co., Ltd, Nanjing Immunophage Biotech Co., Ltd, Kyverna Therapeutics, Century Therapeutics, Adicet Bio, Resolve Therapeutics, Dragonfly Therapeutics, Kite, A Gilead Company, Regeneron Pharmaceuticals Inc., <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b06zJNqNS9UE3IC_r8RCag7N6SREkWgD9Pcy8CJfyTMPlTlVJZINdue2TISMJYBllVni6a-zcCXHm0NDoJOPi1doyf61ElhNQKfnNj_aO8AzVU7D0O_Dhjn-EUIqDlYscNUBeW7d5XZikBcwq9Y6i_wBZ6hOehYWLdqYoHrDhgnL7eY03FznuVxLtbPQTjn_3YlIT2bzbaZQ-l2ViR2PZgDdIJPwEMychzrSY7hUSVP5Oe2xm5Um4AKhXry2Th2i08k6TJ9TqSYuEGMmLSCSEA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Systemic Lupus Erythematosus Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast \u2013 2036<\/b> report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key SLE companies including <b>Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b06zJNqNS9UE3IC_r8RCag7N6SREkWgD9Pcy8CJfyTMR9gPP1krs96G4NdJHLrUh9e86EDzMWM-r_q_JlM20ol97N_JxQLhQizp876H5uWRYn2lNTnNnXN5q81e-VmTee-uhneDsBXt70b5xx0J_d9Uy47S1SQmetajefU0uRM_thg7_MLeEOPZIP0jEpgY_KhQstppn7dyZNHaAqmDi0QSEalpuV74CmEZWEkpuv1Y4lTEEziVLAb8Y5ZtbdlarwavgUaQc8DW_beHkdt6G9iDWIgl-fZXITu1Dbbomtum5haQsEH4AepSneSn2zunI\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Systemic Lupus Erythematosus Clinical Trial Analysis<\/b><\/a><\/p>\n<p align=\"justify\"><b>Systemic Lupus Erythematosus Pipeline Insight \u2013 2026<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key SLE companies, including <b>Roche, Biogen, Viatris Inc., Novartis, Qilu Pharmaceutical, ImmuPharma, Beijing Mabworks Biotech Co., Ltd., Zenas Biopharma, AbbVie, Beijing InnoCare Pharma Tech Co., Ltd., Alumis Inc., Galapagos NV, Palleon Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Johnson &amp; Johnson, Merck KGaA, Resolve Therapeutics, ILTOO Pharma, Argenx, Cartesian Therapeutics, Keymed Biosciences Co., Ltd, BioSenic, Eisai, Vertex Pharmaceuticals, Kyverna Therapeutics, Miltenyi Biomedicine, Astrazeneca, Otsuka Pharmaceutical, Fresh Tracks Therapeutics, Nucleome Therapeutics, OMass Therapeutics, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CsL-cOBW1XwiUt-wLcxZCuMRnEeRPEOyb6eDF3GtrBaHoBX9YuKdnJiAMhUQr6QlH4T1--iL-obEJlzBRXIVV7zNRgYnWpumJ3KZF58WcXCR4H1XKKTuy9_bS31q3LFEIP4xPoGX1n4mPO0qiVLDFirimHzAur0uSUEpAG9iIAw5INpUzy17NoEllJC6SJ97ksEiPZgMjI2E2lwMAFuPxXKZf_5BsNzOgqZxK8x1lCL8CFetMQaz0GyEIf7cBl-w\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>IgA Nephropathy Market\u00a0<\/b><\/a><\/p>\n<p align=\"justify\"><b>IgA Nephropathy Market Insights, Epidemiology, and Market Forecast \u2013 2036<\/b> report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key IgAN companies including <b>Novartis, F. Hoffmann-La Roche, Ionis Pharmaceuticals, AstraZeneca (Alexion Pharmaceuticals), Vertex Pharmaceuticals, Otsuka Pharmaceutical, Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CsL-cOBW1XwiUt-wLcxZCpRwpZNvgRPMeW66ghFgpf_CRG3tzWe5OrqkEy2VgfDzqrB2U3WjVIuAMJNOnqXab-ADW_2kbFXVEV4PU2LUIRhxOcfvDB0IwVkCsl9_qRarxfY0NJsXD3TfSODr6Do_WVdkjvaLmbcIY1G6R4AWvmJRaLb3UN9mbpuhq-rJUhztEwBEbVmrE2K0g8BsV0MswfLoM5AKYUXFgdDx1nJNtW_GYoRkus_wM6rS1yVhJdeSidaSqF-OrmW2gWlwSLTlBalhJzCXngfgMLNZ2B92Al0=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>IgA Nephropathy Clinical Trial Analysis<\/b><\/a><\/p>\n<p align=\"justify\"><b>IgA Nephropathy Pipeline Insight \u2013 2026<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key IgAN companies, including <b>Novartis Pharmaceuticals, Biohaven, Ltd., Keymed Biosciences Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., ADARx Pharmaceuticals Inc., Biogen, Suzhou Rigerna Therapeutics, Wuxi BioCity Biopharmaceutics Co., Ltd., Transcenta Holding, Climb Bio, Chengdu Suncadia Medicine Co., Ltd., Purespring Therapeutics, <\/b>and others.<\/p>\n<p align=\"justify\"><b>About\u00a0DelveInsight<\/b><\/p>\n<p align=\"justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve<b>.<\/b><\/p>\n<pre>CONTACT: Contact Us\n\nShruti Thakur\u00a0\n\ninfo@delveinsight.com\u00a0\n\n+14699457679<\/pre>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/MDhlMDNlYmUtYzVmNC00ZDFhLWI2ZTgtNjdmMTZhYjA3ZDhjLTEyMDQ5MzgtMjAyNi0wOS0xNC1lbg==\/tiny\/DelveInsight-Business-Research.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The treatment landscape is evolving beyond conventional broad-spectrum immunosuppressants, with approved therapies such as belimumab, voclosporin, and obinutuzumab expanding treatment options for patients with active disease. At the [&#8230;]\n","protected":false},"author":1,"featured_media":84757,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-84756","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026\u20132036), as Innovative Therapies Gain Momentum | DelveInsight - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026\u20132036), as Innovative Therapies Gain Momentum | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-14T17:44:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-14T23:58:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/09\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026\u20132036), as Innovative Therapies Gain Momentum | DelveInsight\",\"datePublished\":\"2026-09-14T17:44:00+00:00\",\"dateModified\":\"2026-09-14T23:58:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/\"},\"wordCount\":2666,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/\",\"name\":\"Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026\u20132036), as Innovative Therapies Gain Momentum | DelveInsight - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-09-14T17:44:00+00:00\",\"dateModified\":\"2026-09-14T23:58:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026\u20132036), as Innovative Therapies Gain Momentum | DelveInsight\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026\u20132036), as Innovative Therapies Gain Momentum | DelveInsight - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/","og_locale":"en_US","og_type":"article","og_title":"Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026\u20132036), as Innovative Therapies Gain Momentum | DelveInsight","og_description":"The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the","og_url":"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-09-14T17:44:00+00:00","article_modified_time":"2026-09-14T23:58:49+00:00","og_image":[{"width":800,"height":420,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/09\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026\u20132036), as Innovative Therapies Gain Momentum | DelveInsight","datePublished":"2026-09-14T17:44:00+00:00","dateModified":"2026-09-14T23:58:49+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/"},"wordCount":2666,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/","url":"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/","name":"Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026\u20132036), as Innovative Therapies Gain Momentum | DelveInsight - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-09-14T17:44:00+00:00","dateModified":"2026-09-14T23:58:49+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/lupus-nephritis-market-on-a-growth-trajectory-at-a-cagr-of-7-during-the-forecast-period-2026-2036-as-innovative-therapies-gain-momentum-delveinsight\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026\u20132036), as Innovative Therapies Gain Momentum | DelveInsight"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/84756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=84756"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/84756\/revisions"}],"predecessor-version":[{"id":84758,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/84756\/revisions\/84758"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/84757"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=84756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=84756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=84756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}